Cannabinoid compounds reduced physical morphine withdrawal signs in mice but not the emotional aversion to withdrawal

THC and endocannabinoid-boosting drugs reduced physical withdrawal jumping in morphine-dependent mice but did not block the aversive emotional experience of withdrawal.

Gamage, Thomas F et al.·Drug and alcohol dependence·2015·Preliminary EvidenceAnimal StudyAnimal Study
RTHC-00962Animal StudyPreliminary Evidence2015RETHINKTHC RESEARCH DATABASErethinkthc.com/research

Quick Facts

Study Type
Animal Study
Evidence
Preliminary Evidence
Sample
Not reported

What This Study Found

Researchers tested whether cannabinoid compounds could reduce different aspects of morphine withdrawal in mice. They examined both physical signs (jumping) and emotional aspects (conditioned place avoidance, where mice learn to avoid a location associated with withdrawal).

THC, the MAGL inhibitor JZL184, and the dual FAAH/MAGL inhibitor SA-57 all significantly reduced the percentage of mice that jumped during withdrawal. However, none of these compounds blocked the development of conditioned place avoidance, meaning mice still learned to avoid the withdrawal-associated environment.

The FAAH inhibitor PF-3845 (which boosts anandamide but not 2-AG) did not reduce either physical or emotional withdrawal. Importantly, none of the endocannabinoid-boosting drugs produced a place preference or aversion on their own, suggesting low abuse potential.

Key Numbers

THC, JZL184, and SA-57 reduced jumping but not place avoidance. PF-3845 reduced neither. None produced place preference in non-dependent mice. Morphine pretreatment prevented both physical and emotional withdrawal. Clonidine blocked only emotional withdrawal.

How They Did This

Controlled animal study using morphine-pelleted mice with naloxone-precipitated withdrawal. THC, JZL184 (MAGL inhibitor), PF-3845 (FAAH inhibitor), and SA-57 (dual inhibitor) were tested against conditioned place avoidance (emotional withdrawal) and jumping behavior (physical withdrawal). Non-dependent mice were tested for place preference/aversion.

Why This Research Matters

Separating physical and emotional aspects of withdrawal reveals that cannabinoids may help with some but not all dimensions of opioid withdrawal. This has implications for whether cannabinoid-based treatments could meaningfully improve the opioid withdrawal experience.

The Bigger Picture

Opioid withdrawal has both physical and emotional components, and effective treatment needs to address both. This study shows that cannabinoid approaches may help with physical symptoms while leaving emotional distress intact, suggesting they would be insufficient as standalone withdrawal treatments.

What This Study Doesn't Tell Us

Mouse model may not fully capture human withdrawal experience. Precipitated withdrawal (using naloxone) is more abrupt than natural withdrawal. Drug doses were specific and may not represent optimal therapeutic ranges. The conditioned place avoidance paradigm measures one specific aspect of emotional response.

Questions This Raises

  • ?Could higher doses or different cannabinoid compounds address emotional withdrawal?
  • ?Would combining cannabinoids with clonidine (which blocked emotional but not physical aspects) provide comprehensive withdrawal relief?
  • ?Do these findings translate to human opioid withdrawal?

Trust & Context

Key Stat:
Physical withdrawal reduced; emotional aversion unchanged
Evidence Grade:
Controlled animal study with multiple compounds and behavioral endpoints. Mechanistically informative but limited human translatability.
Study Age:
Published in 2015. Cannabinoid-opioid interaction research has continued.
Original Title:
Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.
Published In:
Drug and alcohol dependence, 146, 7-16 (2015)
Database ID:
RTHC-00962

Evidence Hierarchy

Meta-Analysis / Systematic Review
Randomized Controlled Trial
Cohort / Case-Control
Cross-Sectional / Observational
Case Report / Animal StudyOne case or non-human subjects
This study

Tests effects in animals (usually mice or rats), not humans.

What do these levels mean? →

Frequently Asked Questions

Can cannabinoids help with opioid withdrawal?

In mice, THC and drugs that boost endocannabinoid levels reduced physical withdrawal symptoms (jumping) but did not address the emotional distress of withdrawal. This suggests cannabinoids may help partially but are not a complete solution.

Do endocannabinoid-boosting drugs have abuse potential?

In this study, none of the endocannabinoid-boosting drugs produced a place preference in non-dependent mice, suggesting they may have lower abuse potential than direct cannabinoid receptor agonists like THC.

Read More on RethinkTHC

Cite This Study

RTHC-00962·https://rethinkthc.com/research/RTHC-00962

APA

Gamage, Thomas F; Ignatowska-Jankowska, Bogna M; Muldoon, Pretal P; Cravatt, Benjamin F; Damaj, M Imad; Lichtman, Aron H. (2015). Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.. Drug and alcohol dependence, 146, 7-16. https://doi.org/10.1016/j.drugalcdep.2014.11.015

MLA

Gamage, Thomas F, et al. "Differential effects of endocannabinoid catabolic inhibitors on morphine withdrawal in mice.." Drug and alcohol dependence, 2015. https://doi.org/10.1016/j.drugalcdep.2014.11.015

RethinkTHC

RethinkTHC Research Database. "Differential effects of endocannabinoid catabolic inhibitors..." RTHC-00962. Retrieved from https://rethinkthc.com/research/gamage-2015-differential-effects-of-endocannabinoid

Access the Original Study

Study data sourced from PubMed, a service of the U.S. National Library of Medicine, National Institutes of Health.

This study breakdown was produced by the RethinkTHC research team. We analyze and report published research findings without making health recommendations. All interpretations are based solely on the published abstract and study data.